Author: Ritzmann, F.; Chitirala, P.; Yao, Y.; Krueger, N.; Hoffmann, M.; Zuo, W.; Lammert, F.; Smola, S.; Seiwert, N.; Tov, N.; Alagem, N.; Mozafari, B.; Guenther, K.; Seibert, M.; Hoersch, S.; Volk, T.; Lepper, P. M.; Danziger, G.; Poehlmann, S.; Beisswenger, C.; Herr, C.; Bals, R.
Title: Therapeutic application of alpha-1-antitrypsin in COVID-19 Cord-id: jcekiymg Document date: 2021_4_6
ID: jcekiymg
Snippet: Rationale: The treatment options for COVID-19 patients are sparse and do not show sufficient efficacy. Alpha-1-antitrypsin (AAT) is a multi-functional host-defense protein with anti-proteolytic and anti-inflammatory activities. Objectives: The aim of the present study was to evaluate whether AAT is a suitable candidate for treatment of COVID-19. Methods: AAT and inflammatory markers were measured in the serum of COVID-19 patients. Human cell cultures were employed to determine the cell-based ant
Document: Rationale: The treatment options for COVID-19 patients are sparse and do not show sufficient efficacy. Alpha-1-antitrypsin (AAT) is a multi-functional host-defense protein with anti-proteolytic and anti-inflammatory activities. Objectives: The aim of the present study was to evaluate whether AAT is a suitable candidate for treatment of COVID-19. Methods: AAT and inflammatory markers were measured in the serum of COVID-19 patients. Human cell cultures were employed to determine the cell-based anti-protease activity of AAT and to test whether AAT inhibits the host cell entry of vesicular stomatitis virus (VSV) particles bearing the spike (S) protein of SARS-CoV-2 and the replication of authentic SARS-CoV-2. Inhaled and / or intravenous AAT was applied to nine patients with mild-to-moderate COVID-19. Measurements and Main Results: The serum AAT concentration in COVID-19 patients was increased as compared to control patients. The relative AAT concentrations were decreased in severe COVID-19 or in non-survivors in ratio to inflammatory blood biomarkers. AAT inhibited serine protease activity in human cell cultures, the uptake of VSV-S into airway cell lines and the replication of SARS-CoV-2 in human lung organoids. All patients, who received AAT, survived and showed decreasing respiratory distress, inflammatory markers, and viral load. Conclusion: AAT has anti-SARS-CoV-2 activity in human cell models, is well tolerated in patients with COVID-19 and together with its anti-inflammatory properties might be a good candidate for treatment of COVID-19.
Search related documents:
Co phrase search for related documents- acute host defense and lung disease: 1
- acute phase protein and lung disease: 1, 2
- acute respiratory syndrome coronavirus and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome coronavirus and low number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome coronavirus and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive immune activation and lung disease: 1
- adaptive immune activation innate and lung disease: 1
- address need and low number: 1, 2, 3
- address need and lung disease: 1, 2, 3, 4, 5, 6
- liver injury and low number: 1, 2
- liver injury and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- liver production and lung disease: 1
Co phrase search for related documents, hyperlinks ordered by date